Arikan, A
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers

When interpreting our results, it is important to highlight that GLP-1RAs were associated with a reduced incidence of anxiety disorders, autism, bulimia nervosa, PTSD, and schizophrenia
Thats because GLP-1 medications like Ozempic slow gastric emptying and can alter absorption rates in the gut, which may affect how quickly caffeine enters your bloodstream
Braun LA, Rosenfeldt F
Both tirzepatide and semaglutide lower blood pressure by promoting weight loss